-
EP3237639
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3237639
| EP3237639 - COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CHEMOTHERAPY-RESISTANT CANCERS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 25.09.2020 Database last updated on 02.09.2024 | |
| Former | Examination is in progress Status updated on 07.09.2018 | ||
| Former | Request for examination was made Status updated on 29.09.2017 | ||
| Former | The international publication has been made Status updated on 19.05.2017 | Most recent event Tooltip | 25.09.2020 | Application deemed to be withdrawn | published on 28.10.2020 [2020/44] | Applicant(s) | For:CH
CY
CZ
FR
LI
Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 / US | For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [2017/44] | Inventor(s) | 01 /
WANG, Yulei 1 DNA Way South San Francisco, CA 94080-4990 / US | [2017/44] | Representative(s) | Brodbeck, Michel, et al F. Hoffmann-La Roche AG Patent Department Grenzacherstrasse 124 4070 Basel / CH | [2017/44] | Application number, filing date | 15831106.8 | 22.12.2015 | [2017/44] | WO2015US67427 | Priority number, date | US201462096355P | 23.12.2014 Original published format: US 201462096355 P | US201562200340P | 03.08.2015 Original published format: US 201562200340 P | [2017/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2016106340 | Date: | 30.06.2016 | Language: | EN | [2016/26] | Type: | A2 Application without search report | No.: | EP3237639 | Date: | 01.11.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.06.2016 takes the place of the publication of the European patent application. | [2017/44] | Search report(s) | International search report - published on: | EP | 01.09.2016 | Classification | IPC: | C12Q1/68 | [2017/44] | CPC: |
C12Q1/6886 (EP,CN,KR,RU,US);
A61K31/337 (RU,US);
A61K31/4745 (US);
A61K31/495 (US);
A61K31/7068 (US);
A61K33/243 (EP,CN,RU,US);
A61K38/212 (EP,RU,US);
A61K39/3955 (CN,US);
A61K45/06 (US);
A61P1/00 (EP);
A61P11/00 (EP);
A61P13/12 (EP);
A61P15/00 (EP);
A61P15/02 (EP);
A61P25/00 (EP);
A61P35/00 (EP);
C07K16/18 (US);
C07K16/22 (US);
C12Q1/6806 (RU);
G01N33/57449 (RU,US);
C07K2317/24 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/44] | Title | German: | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG UND DIAGNOSTIZIERUNG VON CHEMOTHERAPIERESISTENTEM KREBS | [2017/44] | English: | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CHEMOTHERAPY-RESISTANT CANCERS | [2017/44] | French: | COMPOSITIONS ET MÉTHODES DESTINÉES À TRAITER ET À DIAGNOSTIQUER DES CANCERS RÉSISTANT À LA CHIMIOTHÉRAPIE | [2017/44] | Entry into regional phase | 24.07.2017 | National basic fee paid | 24.07.2017 | Designation fee(s) paid | 24.07.2017 | Examination fee paid | Examination procedure | 18.05.2017 | Date on which the examining division has become responsible | 24.07.2017 | Examination requested [2017/44] | 02.02.2018 | Amendment by applicant (claims and/or description) | 06.09.2018 | Despatch of a communication from the examining division (Time limit: M06) | 06.03.2019 | Reply to a communication from the examining division | 18.09.2019 | Despatch of a communication from the examining division (Time limit: M06) | 03.06.2020 | Application deemed to be withdrawn, date of legal effect [2020/44] | 24.06.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2020/44] | Fees paid | Renewal fee | 08.12.2017 | Renewal fee patent year 03 | 10.12.2018 | Renewal fee patent year 04 | 10.12.2019 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2009074968 (ECOLE POLYTECH [CH], et al) [X] 1,3-9,14,15,17,18,20-22,24-41,47-56 * the whole document *; | [X]WO2011153345 (BETH ISRAEL HOSPITAL [US], et al) [X] 1,3-9,14,15,17,18,20-22,24-41,47-56 * the whole document *; | [X]WO2014062978 (CEDARS SINAI MEDICAL CENTER [US]) [X] 1-12,14-18,20-44,47-62 * the whole document *; | [A] - ZHENHUA HU ET AL, "High Expression of Lewis y Antigen and CD44 Is Correlated with Resistance to Chemotherapy in Epithelial Ovarian Cancers", PLOS ONE, (20130228), vol. 8, no. 2, doi:10.1371/journal.pone.0057250, pages 1 - 7, XP055266406 [A] 1-62 * the whole document * DOI: http://dx.doi.org/10.1371/journal.pone.0057250 | [A] - L'ESPERANCE SYLVAIN ET AL, "Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: Molecular signatures of chemoresistant tumors", INTERNATIONAL JOURNAL OF ONCOLOGY, (200607), vol. 29, no. 1, pages 5 - 24, XP055208986 [A] 1-62 * the whole document * DOI: http://dx.doi.org/10.3892/ijo.29.1.5 | [A] - HELLEMAN J ET AL, "Integrated genomics of chemotherapy resistant ovarian cancer: A role for extracellular matrix, TGFbeta and regulating microRNAs", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, PERGAMON, GB, vol. 42, no. 1, doi:10.1016/J.BIOCEL.2009.10.016, ISSN 1357-2725, (20100101), pages 25 - 30, (20091023), XP026909601 [A] 1-62 * the whole document * DOI: http://dx.doi.org/10.1016/j.biocel.2009.10.016 | [X] - RADOSLAW JANUCHOWSKI ET AL, "Microarray-based detection and expression analysis of extracellular matrix proteins in drug-resistant ovarian cancer cell lines", ONCOLOGY REPORTS, GR, (20140101), vol. 32, doi:10.3892/or.2014.3468, ISSN 1021-335X, pages 1981 - 1990, XP055266374 [X] 1-5,7 * the whole document * DOI: http://dx.doi.org/10.3892/or.2014.3468 | [X] - RIESTER MARKUS ET AL, "Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples", JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, (201405), vol. 106, no. 5, XP002756768 [X] 1-7,9,20,22,24,26-30,39-41,57,58,60,62 * the whole document * | [X] - KARLAN BETH Y ET AL, "POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer", GYNECOLOGIC ONCOLOGY, (201402), vol. 132, no. 2, pages 334 - 342, XP028611624 [X] 1-7,9,20,22,24,26-30,39-41,57,58,60,62 * the whole document * DOI: http://dx.doi.org/10.1016/j.ygyno.2013.12.021 | [X] - CHEON D-J ET AL, "Ten-gene biomarker panel: A new hope for ovarian cancer?", BIOMARKERS IN MEDICINE, FUTURE MEDICINE, UK, (20140401), vol. 8, no. 4, doi:10.2217/BMM.14.16, ISSN 1752-0363, pages 523 - 526, XP008174811 [X] 1-7,9,20,22,24,26-30,39-41,57,58,60,62 * the whole document * DOI: http://dx.doi.org/10.2217/bmm.14.16 | Examination | WO2014087156 | by applicant | US2001236388 | WO8906692 | US4892538 | US4943533 | US5212290 | WO9325673 | US5283187 | WO9410202 | EP0659439 | US5457105 | WO9527062 | US5475001 | WO9603397 | WO9607321 | US5500362 | WO9630347 | WO9630046 | WO9633978 | WO9633980 | WO9640210 | US5616582 | US5654307 | US5679683 | WO9738983 | WO9814451 | US5747498 | US5760041 | US5770599 | US5804396 | WO9843960 | WO9845332 | WO9850433 | WO9850038 | US5866572 | WO9906378 | WO9906396 | WO9909016 | US5891996 | WO9924037 | US6002008 | US6054297 | US6084095 | US6140332 | US6235883 | US6265410 | US6344459 | US6344455 | EP0666868 | US6391874 | US6399602 | US6455534 | US6521620 | US6582959 | US6596726 | US6602863 | US2003190317 | WO03086467 | US2003203409 | US2003206899 | US6703020 | US6713484 | WO2005012359 | US6884879 | US2005112126 | US2005186208 | US2006009360 | US7060269 | US2012156194 | - ANGEW CHEM. INTL. ED. ENGL., (1994), vol. 33, pages 183 - 186 | - STRAGLIOTTO ET AL., EUR. J. CANCER, (1996), vol. 32A, pages 636 - 640 | - JOHNS ET AL., J. BIOL. CHEM., (2004), vol. 279, no. 29, pages 30375 - 30384 | - KABAT ET AL., Sequences of Proteins of Immunological Interest, NIH PUBLICATION 91-3242, (1991), vol. 1-3 | - FLATMAN ET AL., J. CHROMATOGR. B, (2007), vol. 848, pages 79 - 87 | - KINDT ET AL., Kuby Immunology, W.H. FREEMAN AND CO., (2007), page 91 | - PORTOLANO ET AL., J. IMMUNOL., (1993), vol. 150, pages 880 - 887 | - CLARKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628 | - PRESTA ET AL., CANCER RES., (1997), vol. 57, pages 4593 - 4599 | - POPKOV ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, (2004), vol. 288, pages 149 - 164 | - WU ET AL., J. BIOL. CHEM., (1987), vol. 262, page 44294432 | - WAGNER ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 3410 - 3414 | - ANDERSON ET AL., SCIENCE, (1992), vol. 256, pages 808 - 813 | - WANG ET AL., J MOL DIAGN, (2012), vol. 14, pages 22 - 29 | - TOTHILL ET AL., CLIN CANCER RES., (2008), vol. 14, pages 5198 - 5298 | - BOURGON ET AL., CLIN CANCER RES, (2014), vol. 20, pages 2080 - 2091 |